个人中心 - 老虎社区

ALi_BaBa

IP属地：未知

帖子 · 222帖子 · 222
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- ALi_BaBaALi_BaBa
  ·2021-12-17
  Sad
  Nasdaq ends sharply lower as investors dump growth stocks
  * Fed to end bond purchases, signals rate hikes in 2022 * Tech is worst among 11 S&P 500 sector inde
  Nasdaq ends sharply lower as investors dump growth stocks
  2,716 1
  3
  分享
  举报
- ALi_BaBaALi_BaBa
  ·2021-12-16
  Great
  非常抱歉，此主贴已删除
  2,333 评论
  5
  分享
  举报
- ALi_BaBaALi_BaBa
  ·2021-12-15
  Great
  Cathie Wood Loads Up Another $4.3M In This Chinese Tesla Rival
  Popular investment management firm Ark Invest,led by Cathie Wood,on Tuesday, bought more shares in t
  Cathie Wood Loads Up Another $4.3M In This Chinese Tesla Rival
  2,419 评论
  4
  分享
  举报
- ALi_BaBaALi_BaBa
  ·2021-12-13
  Like
  3 Reasons CVS Health Is a Top Dividend Stock to Buy Now
  Adding this unique healthcare conglomerate to your portfolio now could lead to heaps of dividend income down the road.
  3 Reasons CVS Health Is a Top Dividend Stock to Buy Now
  1,311 评论
  点赞
  分享
  举报
- ALi_BaBaALi_BaBa
  ·2021-12-13
  Hi
  3 Reasons CVS Health Is a Top Dividend Stock to Buy Now
  Adding this unique healthcare conglomerate to your portfolio now could lead to heaps of dividend income down the road.
  3 Reasons CVS Health Is a Top Dividend Stock to Buy Now
  2,826 评论
  2
  分享
  举报
- ALi_BaBaALi_BaBa
  ·2021-12-09
  Like
  非常抱歉，此主贴已删除
  2,850 2
  1
  分享
  举报
- ALi_BaBaALi_BaBa
  ·2021-12-07
  Lol
  非常抱歉，此主贴已删除
  1,720 评论
  1
  分享
  举报
- ALi_BaBaALi_BaBa
  ·2021-12-03
  Sad
  非常抱歉，此主贴已删除
  1,652 1
  6
  分享
  举报
- ALi_BaBaALi_BaBa
  ·2021-12-02
  Great
  2 Ridiculously Cheap Dividend Stocks To Buy for 2022
  The S&P 500had its worst day of the year on Friday, falling 900 points on the news that there could
  2 Ridiculously Cheap Dividend Stocks To Buy for 2022
  2,212 1
  3
  分享
  举报
- ALi_BaBaALi_BaBa
  ·2021-12-01
  Sad
  Regeneron's COVID-19 antibody drug may be less effective against Omicron
  Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag
  Regeneron's COVID-19 antibody drug may be less effective against Omicron
  1,495 评论
  4
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3564105303063302","uuid":"3564105303063302","gmtCreate":1601011280020,"gmtModify":1611395862509,"name":"ALi_BaBa","pinyin":"alibabaalibaba","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":18,"headSize":552,"tweetSize":222,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.25","exceedPercentage":"93.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":690769005,"gmtCreate":1639709658624,"gmtModify":1639709721510,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690769005","repostId":"2192920942","repostType":4,"repost":{"id":"2192920942","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639694745,"share":"https://ttm.financial/m/news/2192920942?lang=&edition=full","pubTime":"2021-12-17 06:45","market":"us","language":"en","title":"Nasdaq ends sharply lower as investors dump growth stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2192920942","media":"Reuters","summary":"* Fed to end bond purchases, signals rate hikes in 2022\n* Tech is worst among 11 S&P 500 sector inde","content":"<p>* Fed to end bond purchases, signals rate hikes in 2022</p>\n<p>* Tech is worst among 11 S&amp;P 500 sector indexes, financials rally</p>\n<p>* Lennar slips after missing quarterly profit</p>\n<p>* Indexes: Dow -0.08%, S&amp;P 500 -0.87%, Nasdaq -2.47%</p>\n<p>Dec 16 (Reuters) - The Nasdaq ended sharply lower on Thursday as the Federal Reserve's announcement of a faster end to its pandemic-era stimulus pushed investors away from Big Tech and toward more economically sensitive sectors.</p>\n<p>Nvidia,Apple,Microsoft, Amazon&nbsp;and Tesla&nbsp;tumbled between 2.6% and 6.8%, hitting the Nasdaq&nbsp;and the S&amp;P 500, while the Dow Jones Industrial Average declined marginally.</p>\n<p>Most of those heavyweight growth stocks have outperformed the broader market in 2021, with Nvidia up more than 100% year to date.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 0.08% to end at 35,897.64, while the S&amp;P 500&nbsp;lost 0.87% to 4,668.67.</p>\n<p>The Nasdaq Composite&nbsp;dropped 2.47% to 15,180.44.</p>\n<p>The U.S. central bank said on Wednesday it would end its bond purchases in March and signaled three quarter-percentage-point interest rate hikes by the end of 2022.</p>\n<p>That pleased investors who have increasingly worried about an inflation spike related to the coronavirus pandemic. But on Thursday it contributed to the sell-off in growth stocks.</p>\n<p>The S&amp;P 500 value index&nbsp;climbed 0.7%, while the growth index fell 2.1%, reflecting investors' views that high-growth stocks tend to underperform when interest rates rise. The value index includes stocks seen as more likely to do well during an economic recovery.</p>\n<p>\"You're seeing money come out of growth, as it should. If we are going into an environment where interest rates are going up, growth stocks are going to be less attractive\" said Dennis Dick, a trader at Bright Trading LLC.</p>\n<p>\"There's a lot of uncertainty as we go into 2022... We're going to have a more hawkish Fed that is going to pull away the punch bowl,\" he said.</p>\n<p>Among the 11 major S&amp;P 500 sector indexes, technology&nbsp;slumped 2.9%, while financials&nbsp;rallied 1.2%. Eight of the sectors gained, even as the overall index fell.</p>\n<p>\"The Fed gave the market what it wanted, and today I think investors are turning again to pandemic uncertainty, and they're also cautious going into the end of the year,\" said Lindsey Bell, chief investment strategist at Ally Invest, in Charlotte, North Carolina.</p>\n<p>Recent readings on surging producer and consumer prices, as well as the fast-spreading Omicron variant of the coronavirus, have fueled anxiety. The S&amp;P 500, nonetheless, remains up about 25% in 2021 and it is trading near record highs.</p>\n<p>The CBOE Volatility index, often considered Wall Street's fear gauge, slipped to a three-week low.</p>\n<p>Data showed the number of Americans filing new claims for unemployment benefits increased moderately last week, remaining at levels consistent with tightening labor market conditions.</p>\n<p>Separately, a survey showed production at U.S. factories increased to the highest level in nearly three years in November.</p>\n<p>Lennar Corp&nbsp;fell 4.1% after the homebuilder missed analysts' estimates for quarterly profit as pandemic-led supply chain issues pushed lumber costs higher and delayed house deliveries.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.03-to-1 ratio; on Nasdaq, a 1.93-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 69 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 43 new highs and 184 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, in line with the average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq ends sharply lower as investors dump growth stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq ends sharply lower as investors dump growth stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-17 06:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Fed to end bond purchases, signals rate hikes in 2022</p>\n<p>* Tech is worst among 11 S&amp;P 500 sector indexes, financials rally</p>\n<p>* Lennar slips after missing quarterly profit</p>\n<p>* Indexes: Dow -0.08%, S&amp;P 500 -0.87%, Nasdaq -2.47%</p>\n<p>Dec 16 (Reuters) - The Nasdaq ended sharply lower on Thursday as the Federal Reserve's announcement of a faster end to its pandemic-era stimulus pushed investors away from Big Tech and toward more economically sensitive sectors.</p>\n<p>Nvidia,Apple,Microsoft, Amazon&nbsp;and Tesla&nbsp;tumbled between 2.6% and 6.8%, hitting the Nasdaq&nbsp;and the S&amp;P 500, while the Dow Jones Industrial Average declined marginally.</p>\n<p>Most of those heavyweight growth stocks have outperformed the broader market in 2021, with Nvidia up more than 100% year to date.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 0.08% to end at 35,897.64, while the S&amp;P 500&nbsp;lost 0.87% to 4,668.67.</p>\n<p>The Nasdaq Composite&nbsp;dropped 2.47% to 15,180.44.</p>\n<p>The U.S. central bank said on Wednesday it would end its bond purchases in March and signaled three quarter-percentage-point interest rate hikes by the end of 2022.</p>\n<p>That pleased investors who have increasingly worried about an inflation spike related to the coronavirus pandemic. But on Thursday it contributed to the sell-off in growth stocks.</p>\n<p>The S&amp;P 500 value index&nbsp;climbed 0.7%, while the growth index fell 2.1%, reflecting investors' views that high-growth stocks tend to underperform when interest rates rise. The value index includes stocks seen as more likely to do well during an economic recovery.</p>\n<p>\"You're seeing money come out of growth, as it should. If we are going into an environment where interest rates are going up, growth stocks are going to be less attractive\" said Dennis Dick, a trader at Bright Trading LLC.</p>\n<p>\"There's a lot of uncertainty as we go into 2022... We're going to have a more hawkish Fed that is going to pull away the punch bowl,\" he said.</p>\n<p>Among the 11 major S&amp;P 500 sector indexes, technology&nbsp;slumped 2.9%, while financials&nbsp;rallied 1.2%. Eight of the sectors gained, even as the overall index fell.</p>\n<p>\"The Fed gave the market what it wanted, and today I think investors are turning again to pandemic uncertainty, and they're also cautious going into the end of the year,\" said Lindsey Bell, chief investment strategist at Ally Invest, in Charlotte, North Carolina.</p>\n<p>Recent readings on surging producer and consumer prices, as well as the fast-spreading Omicron variant of the coronavirus, have fueled anxiety. The S&amp;P 500, nonetheless, remains up about 25% in 2021 and it is trading near record highs.</p>\n<p>The CBOE Volatility index, often considered Wall Street's fear gauge, slipped to a three-week low.</p>\n<p>Data showed the number of Americans filing new claims for unemployment benefits increased moderately last week, remaining at levels consistent with tightening labor market conditions.</p>\n<p>Separately, a survey showed production at U.S. factories increased to the highest level in nearly three years in November.</p>\n<p>Lennar Corp&nbsp;fell 4.1% after the homebuilder missed analysts' estimates for quarterly profit as pandemic-led supply chain issues pushed lumber costs higher and delayed house deliveries.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.03-to-1 ratio; on Nasdaq, a 1.93-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 69 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 43 new highs and 184 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, in line with the average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","TSLA":"特斯拉",".SPX":"S&P 500 Index","BK4524":"宅经济概念","DXD":"道指两倍做空ETF","SPXU":"三倍做空标普500ETF","BK4554":"元宇宙及AR概念","BK4543":"AI","BK4501":"段永平概念","BK4527":"明星科技股","SSO":"两倍做多标普500ETF","BK4553":"喜马拉雅资本持仓","SDOW":"道指三倍做空ETF-ProShares","BK4099":"汽车制造商","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","LEN":"莱纳建筑公司","UDOW":"道指三倍做多ETF-ProShares","PSQ":"纳指反向ETF","IVV":"标普500指数ETF","BK4503":"景林资产持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","SH":"标普500反向ETF","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","DOG":"道指反向ETF","SQQQ":"纳指三倍做空ETF","OEX":"标普100","BK4505":"高瓴资本持仓","BK4515":"5G概念","BK4504":"桥水持仓","UPRO":"三倍做多标普500ETF","BK4559":"巴菲特持仓","BK4538":"云计算","TQQQ":"纳指三倍做多ETF","AMZN":"亚马逊","BK4088":"住宅建筑","BK4549":"软银资本持仓","BK4548":"巴美列捷福持仓",".DJI":"道琼斯","QQQ":"纳指100ETF","BK4561":"索罗斯持仓","BK4551":"寇图资本持仓",".IXIC":"NASDAQ Composite","DDM":"道指两倍做多ETF","NVDA":"英伟达"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192920942","content_text":"* Fed to end bond purchases, signals rate hikes in 2022\n* Tech is worst among 11 S&P 500 sector indexes, financials rally\n* Lennar slips after missing quarterly profit\n* Indexes: Dow -0.08%, S&P 500 -0.87%, Nasdaq -2.47%\nDec 16 (Reuters) - The Nasdaq ended sharply lower on Thursday as the Federal Reserve's announcement of a faster end to its pandemic-era stimulus pushed investors away from Big Tech and toward more economically sensitive sectors.\nNvidia,Apple,Microsoft, Amazon and Tesla tumbled between 2.6% and 6.8%, hitting the Nasdaq and the S&P 500, while the Dow Jones Industrial Average declined marginally.\nMost of those heavyweight growth stocks have outperformed the broader market in 2021, with Nvidia up more than 100% year to date.\nThe Dow Jones Industrial Average fell 0.08% to end at 35,897.64, while the S&P 500 lost 0.87% to 4,668.67.\nThe Nasdaq Composite dropped 2.47% to 15,180.44.\nThe U.S. central bank said on Wednesday it would end its bond purchases in March and signaled three quarter-percentage-point interest rate hikes by the end of 2022.\nThat pleased investors who have increasingly worried about an inflation spike related to the coronavirus pandemic. But on Thursday it contributed to the sell-off in growth stocks.\nThe S&P 500 value index climbed 0.7%, while the growth index fell 2.1%, reflecting investors' views that high-growth stocks tend to underperform when interest rates rise. The value index includes stocks seen as more likely to do well during an economic recovery.\n\"You're seeing money come out of growth, as it should. If we are going into an environment where interest rates are going up, growth stocks are going to be less attractive\" said Dennis Dick, a trader at Bright Trading LLC.\n\"There's a lot of uncertainty as we go into 2022... We're going to have a more hawkish Fed that is going to pull away the punch bowl,\" he said.\nAmong the 11 major S&P 500 sector indexes, technology slumped 2.9%, while financials rallied 1.2%. Eight of the sectors gained, even as the overall index fell.\n\"The Fed gave the market what it wanted, and today I think investors are turning again to pandemic uncertainty, and they're also cautious going into the end of the year,\" said Lindsey Bell, chief investment strategist at Ally Invest, in Charlotte, North Carolina.\nRecent readings on surging producer and consumer prices, as well as the fast-spreading Omicron variant of the coronavirus, have fueled anxiety. The S&P 500, nonetheless, remains up about 25% in 2021 and it is trading near record highs.\nThe CBOE Volatility index, often considered Wall Street's fear gauge, slipped to a three-week low.\nData showed the number of Americans filing new claims for unemployment benefits increased moderately last week, remaining at levels consistent with tightening labor market conditions.\nSeparately, a survey showed production at U.S. factories increased to the highest level in nearly three years in November.\nLennar Corp fell 4.1% after the homebuilder missed analysts' estimates for quarterly profit as pandemic-led supply chain issues pushed lumber costs higher and delayed house deliveries.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.03-to-1 ratio; on Nasdaq, a 1.93-to-1 ratio favored decliners.\nThe S&P 500 posted 69 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 43 new highs and 184 new lows.\nVolume on U.S. exchanges was 11.6 billion shares, in line with the average over the last 20 trading days.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".DJI":0.9,".IXIC":0.9,".SPX":0.9,"AMZN":0.9,"DDM":0.9,"DOG":0.9,"DXD":0.9,"ESmain":0.9,"MNQmain":0.9,"NQmain":0.9,"IVV":0.9,"LEN":0.9,"NVDA":0.9,"OEF":0.9,"OEX":0.9,"PSQ":0.9,"QQQ":0.9,"SDOW":0.9,"SDS":0.9,"SH":0.9,"SPXU":0.9,"SQQQ":0.9,"SSO":0.9,"TQQQ":0.9,"TSLA":0.9,"UDOW":0.9,"UPRO":0.9}},"isVote":1,"tweetType":1,"viewCount":2716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690005827,"gmtCreate":1639611295764,"gmtModify":1639611295966,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690005827","repostId":"1117099747","repostType":4,"isVote":1,"tweetType":1,"viewCount":2333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607249932,"gmtCreate":1639551927828,"gmtModify":1639551928057,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607249932","repostId":"1160618167","repostType":4,"repost":{"id":"1160618167","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639551825,"share":"https://ttm.financial/m/news/1160618167?lang=&edition=full","pubTime":"2021-12-15 15:03","market":"us","language":"en","title":"Cathie Wood Loads Up Another $4.3M In This Chinese Tesla Rival","url":"https://stock-news.laohu8.com/highlight/detail?id=1160618167","media":"Benzinga","summary":"Popular investment management firm Ark Invest,led by Cathie Wood,on Tuesday, bought more shares in t","content":"<p>Popular investment&nbsp;management firm&nbsp;<b>Ark Invest,</b>led by&nbsp;<b>Cathie Wood,</b>on Tuesday, bought more shares in the U.S. listed Chinese electric vehicle maker&nbsp;<b>Xpeng Inc</b>(NYSE:XPEV) on the dip.</p>\n<p>Ark Invest bought 97,697 shares — estimated to be worth $4.34 million — in the Guangzhou, China-based Xpeng.</p>\n<p>Xpeng’s stock closed 1.92% lower at $44.47 a share on Tuesday and has fallen 7.35% in the past five days.</p>\n<p>Xpeng and other Chinese peer shares such as&nbsp;<b>Nio Inc</b>(NYSE:NIO) have been under pressure recently.</p>\n<p>Xpeng bolted ahead of local rivals Nio and&nbsp;<b>Li Auto Inc</b>(NASDAQ:LI) in terms of monthly volume when it reported November deliveries.</p>\n<p>Each of the three players said they delivered more than 10,000 electric vehicles — with Xpeng leading the pack at 15,613 units, Li Auto grabbing the second spot at 13,485 units and Nio dispatching 10,878 units to dealers during the month.</p>\n<p>Xpeng Chairman Brian Gu last month said the company aims to sell half of its electric vehicles outside of China.</p>\n<p>The maker of electric sedans and SUVs already sells electric vehicles in Norway and plans to ramp up investments overseas next year, including in Sweden, Denmark and the Netherlands.</p>\n<p>Ark Invest bought shares in Xpeng via the&nbsp;<b>ArkAutonomous Technology &amp; Robotics ETF</b>.</p>\n<p>ARKQ held 524,034 shares — worth $23.74 million in Xpeng, prior to Tuesday’s trade.</p>\n<p><b>Tesla Inc</b>&nbsp;is the only other all-electric vehicle manufacturer in which Ark Invest has bought large amounts. The firm counts Tesla as its largest holding and owns shares worth billions in the company via its exchange-traded funds.</p>\n<p>The investment firm has been booking profit in Tesla since early September when shares of the company began an upward march.</p>\n<p>Tesla stock has slipped below the $1,000 levels and its market cap is now below $1-trillion as well.</p>\n<p>Here are a few other key Ark trades from Tuesday:</p>\n<ul>\n <li>Bought 11,671 shares — estimated to be worth $3 million — in&nbsp;<b>Coinbase</b>&nbsp;<b>Global Inc</b>. The stock closed 1.79% higher at $255.86 a share on Tuesday.</li>\n <li>Sold 56,925 shares — estimated to be worth $4.4 million — in<b>JD.com Inc</b>. The stock closed 0.51% lower at $77.65 a share.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Loads Up Another $4.3M In This Chinese Tesla Rival</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Loads Up Another $4.3M In This Chinese Tesla Rival\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-15 15:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Popular investment&nbsp;management firm&nbsp;<b>Ark Invest,</b>led by&nbsp;<b>Cathie Wood,</b>on Tuesday, bought more shares in the U.S. listed Chinese electric vehicle maker&nbsp;<b>Xpeng Inc</b>(NYSE:XPEV) on the dip.</p>\n<p>Ark Invest bought 97,697 shares — estimated to be worth $4.34 million — in the Guangzhou, China-based Xpeng.</p>\n<p>Xpeng’s stock closed 1.92% lower at $44.47 a share on Tuesday and has fallen 7.35% in the past five days.</p>\n<p>Xpeng and other Chinese peer shares such as&nbsp;<b>Nio Inc</b>(NYSE:NIO) have been under pressure recently.</p>\n<p>Xpeng bolted ahead of local rivals Nio and&nbsp;<b>Li Auto Inc</b>(NASDAQ:LI) in terms of monthly volume when it reported November deliveries.</p>\n<p>Each of the three players said they delivered more than 10,000 electric vehicles — with Xpeng leading the pack at 15,613 units, Li Auto grabbing the second spot at 13,485 units and Nio dispatching 10,878 units to dealers during the month.</p>\n<p>Xpeng Chairman Brian Gu last month said the company aims to sell half of its electric vehicles outside of China.</p>\n<p>The maker of electric sedans and SUVs already sells electric vehicles in Norway and plans to ramp up investments overseas next year, including in Sweden, Denmark and the Netherlands.</p>\n<p>Ark Invest bought shares in Xpeng via the&nbsp;<b>ArkAutonomous Technology &amp; Robotics ETF</b>.</p>\n<p>ARKQ held 524,034 shares — worth $23.74 million in Xpeng, prior to Tuesday’s trade.</p>\n<p><b>Tesla Inc</b>&nbsp;is the only other all-electric vehicle manufacturer in which Ark Invest has bought large amounts. The firm counts Tesla as its largest holding and owns shares worth billions in the company via its exchange-traded funds.</p>\n<p>The investment firm has been booking profit in Tesla since early September when shares of the company began an upward march.</p>\n<p>Tesla stock has slipped below the $1,000 levels and its market cap is now below $1-trillion as well.</p>\n<p>Here are a few other key Ark trades from Tuesday:</p>\n<ul>\n <li>Bought 11,671 shares — estimated to be worth $3 million — in&nbsp;<b>Coinbase</b>&nbsp;<b>Global Inc</b>. The stock closed 1.79% higher at $255.86 a share on Tuesday.</li>\n <li>Sold 56,925 shares — estimated to be worth $4.4 million — in<b>JD.com Inc</b>. The stock closed 0.51% lower at $77.65 a share.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","ARKQ":"ARK Autonomous Technology & Robotics ETF","JD":"京东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160618167","content_text":"Popular investment management firm Ark Invest,led by Cathie Wood,on Tuesday, bought more shares in the U.S. listed Chinese electric vehicle maker Xpeng Inc(NYSE:XPEV) on the dip.\nArk Invest bought 97,697 shares — estimated to be worth $4.34 million — in the Guangzhou, China-based Xpeng.\nXpeng’s stock closed 1.92% lower at $44.47 a share on Tuesday and has fallen 7.35% in the past five days.\nXpeng and other Chinese peer shares such as Nio Inc(NYSE:NIO) have been under pressure recently.\nXpeng bolted ahead of local rivals Nio and Li Auto Inc(NASDAQ:LI) in terms of monthly volume when it reported November deliveries.\nEach of the three players said they delivered more than 10,000 electric vehicles — with Xpeng leading the pack at 15,613 units, Li Auto grabbing the second spot at 13,485 units and Nio dispatching 10,878 units to dealers during the month.\nXpeng Chairman Brian Gu last month said the company aims to sell half of its electric vehicles outside of China.\nThe maker of electric sedans and SUVs already sells electric vehicles in Norway and plans to ramp up investments overseas next year, including in Sweden, Denmark and the Netherlands.\nArk Invest bought shares in Xpeng via the ArkAutonomous Technology & Robotics ETF.\nARKQ held 524,034 shares — worth $23.74 million in Xpeng, prior to Tuesday’s trade.\nTesla Inc is the only other all-electric vehicle manufacturer in which Ark Invest has bought large amounts. The firm counts Tesla as its largest holding and owns shares worth billions in the company via its exchange-traded funds.\nThe investment firm has been booking profit in Tesla since early September when shares of the company began an upward march.\nTesla stock has slipped below the $1,000 levels and its market cap is now below $1-trillion as well.\nHere are a few other key Ark trades from Tuesday:\n\nBought 11,671 shares — estimated to be worth $3 million — in Coinbase Global Inc. The stock closed 1.79% higher at $255.86 a share on Tuesday.\nSold 56,925 shares — estimated to be worth $4.4 million — inJD.com Inc. The stock closed 0.51% lower at $77.65 a share.","news_type":1,"symbols_score_info":{"ARKQ":0,"JD":0,"XPEV":0}},"isVote":1,"tweetType":1,"viewCount":2419,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604208881,"gmtCreate":1639397221097,"gmtModify":1639397221387,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604208881","repostId":"2191144607","repostType":4,"repost":{"id":"2191144607","kind":"highlight","pubTimestamp":1639396223,"share":"https://ttm.financial/m/news/2191144607?lang=&edition=full","pubTime":"2021-12-13 19:50","market":"us","language":"en","title":"3 Reasons CVS Health Is a Top Dividend Stock to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2191144607","media":"Motley Fool","summary":"Adding this unique healthcare conglomerate to your portfolio now could lead to heaps of dividend income down the road.","content":"<p>Promises made, promises kept. That was <a href=\"https://laohu8.com/S/AONE.U\">one</a> big theme in this year's investor day presentation from <b>CVS Health</b> (NYSE:CVS). Recently, the healthcare giant laid out its plans for the years ahead, and the expectations aren't entirely unreasonable.</p>\n<p>If you've been thinking about adding this dividend-paying stock to your portfolio, now looks like a great time to act for a lot of good reasons. Here are three of the most important ones.</p>\n<h2>1. Dividend raises ahead</h2>\n<p>CVS Health is generally a reliable dividend raiser, but the company froze its payout in place in 2017 to help with the $69 billion acquisition of Aetna in 2018. CVS Health took on a lot of debt to become a healthcare benefits manager and wisely decided to freeze dividend payments in place until its financial leverage ratio reached a more comfortable level.</p>\n<p><img src=\"https://static.tigerbbs.com/ea28b7c44acab1d1bd044a5b4673b282\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>CVS Dividend data by YCharts</p>\n<p>The company's a bit more levered up than it was just ahead of the Aetna acquisition. At a financial leverage ratio below 0.8, though, it's more than likely safe to show shareholders a lot more appreciation.</p>\n<p>Effective Feb. 1, 2022, patient CVS Health shareholders will receive a $0.55 dividend payment or 10% more than they've been receiving since late 2017. Also, the company intends to return $10 billion to investors in the form of share buybacks.</p>\n<p>At recent prices, the impending buybacks could reduce CVS Health's outstanding share count by more than 7% at recent prices. This will make it even easier to bump the payout higher in the years ahead.</p>\n<h2>2. Chance to outdo UnitedHealth</h2>\n<p>Thanks to the Affordable Care Act, private healthcare plan sponsors, Medicare, and Medicaid increasingly pay fixed rates for specific conditions. This means running patients through more tests and services than they need leads to losses on the bottom line for companies like CVS Health. It also means that coordinating primary care in a way that keeps patients healthy and out of the hospital can lead to windfall profits.</p>\n<p><b>UnitedHealth Group</b> (NYSE:UNH) doesn't bring in quite as much revenue as CVS Health, but it's been generating around twice as much net income. A large part of UnitedHealth's rise to the top can be attributed to an internal network of doctors. UnitedHealth employs or at least has a relationship with 60,000 U.S. physicians. Taking money from healthcare plan sponsors and using it to pay providers is a lot easier to manage when you employ the providers.</p>\n<p><img src=\"https://static.tigerbbs.com/5ac3d5c608e51025677678036d4486d5\" tg-width=\"720\" tg-height=\"497\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>CVS Revenue (TTM) data by YCharts</p>\n<p>CVS Health employs more pharmacists than UnitedHealth, but drugs are a relatively minor expense. In 2019, National Health Expenditure data found that prescription drugs made up just 10% of America's $3.8 trillion healthcare bill that year. Physician and clinical services worked out to 21% and hospitals soaked up the largest share at 30% of total healthcare spending.</p>\n<p>With more than 9,000 physical locations spread throughout the U.S., CVS Health has a chance to employ more of the cost-saving measures that UnitedHealth Group enjoys. At the moment, CVS Health manages 1,200 walk-in medical clinics that employ around 4,000 nurse practitioners and physician assistants. It won't happen overnight, but better coordination of primary care could make CVS Health's profit margins resemble United Health's.</p>\n<h2>3. Ability to keep raising the payout</h2>\n<p>At recent prices, CVS Health stock offers a 2.2% yield and a pretty good chance to see that payout rise into the clouds. Over the past year, CVS Health generated a whopping $15.2 billion in free cash flow and used just $2.7 billion to make payments.</p>\n<p>With its debt load under control, the company can raise its dividend payout in line with earnings growth. Vaccine distribution revenue might slacken in the years ahead but growth ahead seems like a reasonable prediction. A steadily aging U.S. population is going to need more healthcare year after year for decades to come.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons CVS Health Is a Top Dividend Stock to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons CVS Health Is a Top Dividend Stock to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 19:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/13/3-reasons-cvs-health-is-top-dividend-stock-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Promises made, promises kept. That was one big theme in this year's investor day presentation from CVS Health (NYSE:CVS). Recently, the healthcare giant laid out its plans for the years ahead, and the...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/13/3-reasons-cvs-health-is-top-dividend-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4504":"桥水持仓","BK4196":"保健护理服务","CVS":"西维斯健康"},"source_url":"https://www.fool.com/investing/2021/12/13/3-reasons-cvs-health-is-top-dividend-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191144607","content_text":"Promises made, promises kept. That was one big theme in this year's investor day presentation from CVS Health (NYSE:CVS). Recently, the healthcare giant laid out its plans for the years ahead, and the expectations aren't entirely unreasonable.\nIf you've been thinking about adding this dividend-paying stock to your portfolio, now looks like a great time to act for a lot of good reasons. Here are three of the most important ones.\n1. Dividend raises ahead\nCVS Health is generally a reliable dividend raiser, but the company froze its payout in place in 2017 to help with the $69 billion acquisition of Aetna in 2018. CVS Health took on a lot of debt to become a healthcare benefits manager and wisely decided to freeze dividend payments in place until its financial leverage ratio reached a more comfortable level.\n\nCVS Dividend data by YCharts\nThe company's a bit more levered up than it was just ahead of the Aetna acquisition. At a financial leverage ratio below 0.8, though, it's more than likely safe to show shareholders a lot more appreciation.\nEffective Feb. 1, 2022, patient CVS Health shareholders will receive a $0.55 dividend payment or 10% more than they've been receiving since late 2017. Also, the company intends to return $10 billion to investors in the form of share buybacks.\nAt recent prices, the impending buybacks could reduce CVS Health's outstanding share count by more than 7% at recent prices. This will make it even easier to bump the payout higher in the years ahead.\n2. Chance to outdo UnitedHealth\nThanks to the Affordable Care Act, private healthcare plan sponsors, Medicare, and Medicaid increasingly pay fixed rates for specific conditions. This means running patients through more tests and services than they need leads to losses on the bottom line for companies like CVS Health. It also means that coordinating primary care in a way that keeps patients healthy and out of the hospital can lead to windfall profits.\nUnitedHealth Group (NYSE:UNH) doesn't bring in quite as much revenue as CVS Health, but it's been generating around twice as much net income. A large part of UnitedHealth's rise to the top can be attributed to an internal network of doctors. UnitedHealth employs or at least has a relationship with 60,000 U.S. physicians. Taking money from healthcare plan sponsors and using it to pay providers is a lot easier to manage when you employ the providers.\n\nCVS Revenue (TTM) data by YCharts\nCVS Health employs more pharmacists than UnitedHealth, but drugs are a relatively minor expense. In 2019, National Health Expenditure data found that prescription drugs made up just 10% of America's $3.8 trillion healthcare bill that year. Physician and clinical services worked out to 21% and hospitals soaked up the largest share at 30% of total healthcare spending.\nWith more than 9,000 physical locations spread throughout the U.S., CVS Health has a chance to employ more of the cost-saving measures that UnitedHealth Group enjoys. At the moment, CVS Health manages 1,200 walk-in medical clinics that employ around 4,000 nurse practitioners and physician assistants. It won't happen overnight, but better coordination of primary care could make CVS Health's profit margins resemble United Health's.\n3. Ability to keep raising the payout\nAt recent prices, CVS Health stock offers a 2.2% yield and a pretty good chance to see that payout rise into the clouds. Over the past year, CVS Health generated a whopping $15.2 billion in free cash flow and used just $2.7 billion to make payments.\nWith its debt load under control, the company can raise its dividend payout in line with earnings growth. Vaccine distribution revenue might slacken in the years ahead but growth ahead seems like a reasonable prediction. A steadily aging U.S. population is going to need more healthcare year after year for decades to come.","news_type":1,"symbols_score_info":{"CVS":0.9}},"isVote":1,"tweetType":1,"viewCount":1311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604208165,"gmtCreate":1639397207286,"gmtModify":1639397207540,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604208165","repostId":"2191144607","repostType":4,"repost":{"id":"2191144607","kind":"highlight","pubTimestamp":1639396223,"share":"https://ttm.financial/m/news/2191144607?lang=&edition=full","pubTime":"2021-12-13 19:50","market":"us","language":"en","title":"3 Reasons CVS Health Is a Top Dividend Stock to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2191144607","media":"Motley Fool","summary":"Adding this unique healthcare conglomerate to your portfolio now could lead to heaps of dividend income down the road.","content":"<p>Promises made, promises kept. That was <a href=\"https://laohu8.com/S/AONE.U\">one</a> big theme in this year's investor day presentation from <b>CVS Health</b> (NYSE:CVS). Recently, the healthcare giant laid out its plans for the years ahead, and the expectations aren't entirely unreasonable.</p>\n<p>If you've been thinking about adding this dividend-paying stock to your portfolio, now looks like a great time to act for a lot of good reasons. Here are three of the most important ones.</p>\n<h2>1. Dividend raises ahead</h2>\n<p>CVS Health is generally a reliable dividend raiser, but the company froze its payout in place in 2017 to help with the $69 billion acquisition of Aetna in 2018. CVS Health took on a lot of debt to become a healthcare benefits manager and wisely decided to freeze dividend payments in place until its financial leverage ratio reached a more comfortable level.</p>\n<p><img src=\"https://static.tigerbbs.com/ea28b7c44acab1d1bd044a5b4673b282\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>CVS Dividend data by YCharts</p>\n<p>The company's a bit more levered up than it was just ahead of the Aetna acquisition. At a financial leverage ratio below 0.8, though, it's more than likely safe to show shareholders a lot more appreciation.</p>\n<p>Effective Feb. 1, 2022, patient CVS Health shareholders will receive a $0.55 dividend payment or 10% more than they've been receiving since late 2017. Also, the company intends to return $10 billion to investors in the form of share buybacks.</p>\n<p>At recent prices, the impending buybacks could reduce CVS Health's outstanding share count by more than 7% at recent prices. This will make it even easier to bump the payout higher in the years ahead.</p>\n<h2>2. Chance to outdo UnitedHealth</h2>\n<p>Thanks to the Affordable Care Act, private healthcare plan sponsors, Medicare, and Medicaid increasingly pay fixed rates for specific conditions. This means running patients through more tests and services than they need leads to losses on the bottom line for companies like CVS Health. It also means that coordinating primary care in a way that keeps patients healthy and out of the hospital can lead to windfall profits.</p>\n<p><b>UnitedHealth Group</b> (NYSE:UNH) doesn't bring in quite as much revenue as CVS Health, but it's been generating around twice as much net income. A large part of UnitedHealth's rise to the top can be attributed to an internal network of doctors. UnitedHealth employs or at least has a relationship with 60,000 U.S. physicians. Taking money from healthcare plan sponsors and using it to pay providers is a lot easier to manage when you employ the providers.</p>\n<p><img src=\"https://static.tigerbbs.com/5ac3d5c608e51025677678036d4486d5\" tg-width=\"720\" tg-height=\"497\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>CVS Revenue (TTM) data by YCharts</p>\n<p>CVS Health employs more pharmacists than UnitedHealth, but drugs are a relatively minor expense. In 2019, National Health Expenditure data found that prescription drugs made up just 10% of America's $3.8 trillion healthcare bill that year. Physician and clinical services worked out to 21% and hospitals soaked up the largest share at 30% of total healthcare spending.</p>\n<p>With more than 9,000 physical locations spread throughout the U.S., CVS Health has a chance to employ more of the cost-saving measures that UnitedHealth Group enjoys. At the moment, CVS Health manages 1,200 walk-in medical clinics that employ around 4,000 nurse practitioners and physician assistants. It won't happen overnight, but better coordination of primary care could make CVS Health's profit margins resemble United Health's.</p>\n<h2>3. Ability to keep raising the payout</h2>\n<p>At recent prices, CVS Health stock offers a 2.2% yield and a pretty good chance to see that payout rise into the clouds. Over the past year, CVS Health generated a whopping $15.2 billion in free cash flow and used just $2.7 billion to make payments.</p>\n<p>With its debt load under control, the company can raise its dividend payout in line with earnings growth. Vaccine distribution revenue might slacken in the years ahead but growth ahead seems like a reasonable prediction. A steadily aging U.S. population is going to need more healthcare year after year for decades to come.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons CVS Health Is a Top Dividend Stock to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons CVS Health Is a Top Dividend Stock to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 19:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/13/3-reasons-cvs-health-is-top-dividend-stock-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Promises made, promises kept. That was one big theme in this year's investor day presentation from CVS Health (NYSE:CVS). Recently, the healthcare giant laid out its plans for the years ahead, and the...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/13/3-reasons-cvs-health-is-top-dividend-stock-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4504":"桥水持仓","BK4196":"保健护理服务","CVS":"西维斯健康"},"source_url":"https://www.fool.com/investing/2021/12/13/3-reasons-cvs-health-is-top-dividend-stock-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191144607","content_text":"Promises made, promises kept. That was one big theme in this year's investor day presentation from CVS Health (NYSE:CVS). Recently, the healthcare giant laid out its plans for the years ahead, and the expectations aren't entirely unreasonable.\nIf you've been thinking about adding this dividend-paying stock to your portfolio, now looks like a great time to act for a lot of good reasons. Here are three of the most important ones.\n1. Dividend raises ahead\nCVS Health is generally a reliable dividend raiser, but the company froze its payout in place in 2017 to help with the $69 billion acquisition of Aetna in 2018. CVS Health took on a lot of debt to become a healthcare benefits manager and wisely decided to freeze dividend payments in place until its financial leverage ratio reached a more comfortable level.\n\nCVS Dividend data by YCharts\nThe company's a bit more levered up than it was just ahead of the Aetna acquisition. At a financial leverage ratio below 0.8, though, it's more than likely safe to show shareholders a lot more appreciation.\nEffective Feb. 1, 2022, patient CVS Health shareholders will receive a $0.55 dividend payment or 10% more than they've been receiving since late 2017. Also, the company intends to return $10 billion to investors in the form of share buybacks.\nAt recent prices, the impending buybacks could reduce CVS Health's outstanding share count by more than 7% at recent prices. This will make it even easier to bump the payout higher in the years ahead.\n2. Chance to outdo UnitedHealth\nThanks to the Affordable Care Act, private healthcare plan sponsors, Medicare, and Medicaid increasingly pay fixed rates for specific conditions. This means running patients through more tests and services than they need leads to losses on the bottom line for companies like CVS Health. It also means that coordinating primary care in a way that keeps patients healthy and out of the hospital can lead to windfall profits.\nUnitedHealth Group (NYSE:UNH) doesn't bring in quite as much revenue as CVS Health, but it's been generating around twice as much net income. A large part of UnitedHealth's rise to the top can be attributed to an internal network of doctors. UnitedHealth employs or at least has a relationship with 60,000 U.S. physicians. Taking money from healthcare plan sponsors and using it to pay providers is a lot easier to manage when you employ the providers.\n\nCVS Revenue (TTM) data by YCharts\nCVS Health employs more pharmacists than UnitedHealth, but drugs are a relatively minor expense. In 2019, National Health Expenditure data found that prescription drugs made up just 10% of America's $3.8 trillion healthcare bill that year. Physician and clinical services worked out to 21% and hospitals soaked up the largest share at 30% of total healthcare spending.\nWith more than 9,000 physical locations spread throughout the U.S., CVS Health has a chance to employ more of the cost-saving measures that UnitedHealth Group enjoys. At the moment, CVS Health manages 1,200 walk-in medical clinics that employ around 4,000 nurse practitioners and physician assistants. It won't happen overnight, but better coordination of primary care could make CVS Health's profit margins resemble United Health's.\n3. Ability to keep raising the payout\nAt recent prices, CVS Health stock offers a 2.2% yield and a pretty good chance to see that payout rise into the clouds. Over the past year, CVS Health generated a whopping $15.2 billion in free cash flow and used just $2.7 billion to make payments.\nWith its debt load under control, the company can raise its dividend payout in line with earnings growth. Vaccine distribution revenue might slacken in the years ahead but growth ahead seems like a reasonable prediction. A steadily aging U.S. population is going to need more healthcare year after year for decades to come.","news_type":1,"symbols_score_info":{"CVS":0.9}},"isVote":1,"tweetType":1,"viewCount":2826,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602557670,"gmtCreate":1639046570900,"gmtModify":1639046571083,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602557670","repostId":"1128116582","repostType":4,"isVote":1,"tweetType":1,"viewCount":2850,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606140542,"gmtCreate":1638846449780,"gmtModify":1638846449968,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606140542","repostId":"1159148044","repostType":4,"isVote":1,"tweetType":1,"viewCount":1720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601192015,"gmtCreate":1638496134744,"gmtModify":1638496134846,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601192015","repostId":"1119529609","repostType":4,"isVote":1,"tweetType":1,"viewCount":1652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603275417,"gmtCreate":1638419977381,"gmtModify":1638419977684,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603275417","repostId":"1182613816","repostType":4,"repost":{"id":"1182613816","kind":"news","pubTimestamp":1638415076,"share":"https://ttm.financial/m/news/1182613816?lang=&edition=full","pubTime":"2021-12-02 11:17","market":"us","language":"en","title":"2 Ridiculously Cheap Dividend Stocks To Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1182613816","media":"Motley Fool","summary":"The S&P 500had its worst day of the year on Friday, falling 900 points on the news that there could ","content":"<p>The&nbsp;<b>S&amp;P 500</b>had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.</p>\n<p>For investors looking to get away from this volatility and find more safety, holding dividend stocks in your portfolio can be an excellent decision. They can ensure that you're collecting a recurring stream of income you can use to help offset losses in your portfolio. And at best, they can boost your returns. Two dividend stocks that pay an above-average yield and are incredibly cheap right now are&nbsp;<b>AbbVie</b>(NYSE:ABBV)and&nbsp;<b>ViacomCBS</b>(NASDAQ:VIAC).</p>\n<p>1. AbbVie</p>\n<p>AbbVie makes for an ideal buy-and-forget investment. The&nbsp;healthcare stock&nbsp;yields an impressive 4.8% right now -- well above the&nbsp;<b>S&amp;P 500</b>average of just 1.4%. And the dividend is well supported; in the past 12 months, the company has generated free cash flow of $21.7 billion, more than double the $9 billion in dividends it paid out during that time.</p>\n<p>When the company released its latest quarterly earnings results on Oct. 29, it reported sales of $14.3 billion, 11% higher than the year-ago period. The company also raised its guidance for a third time in 2021, anticipating that its adjusted diluted earnings per share will come in between $12.63 and $12.67 for the full year. That's well above the $5.64 in dividends that the company is paying out annually per share. TheDividend Aristocratalso raised its dividend by 8.5% in a hike that will come into effect next year.</p>\n<p>While investors may be worried about the company's expiring patent on rhe&nbsp;umatoid arthritis drug Humira, AbbVie's management anticipates that newer drugs like Skyrizi and Rinvoq will generate long-term growth and make up for the inevitable decline in Humira's sales. Both drugs still have a long way to go. In just the latest quarter, they achieved combined sales of $1.2 billion in sales while Humira brought in more than $5.4 billion.</p>\n<p>CEO Richard Gonzalez said, \"What we're basically trying to accomplish with the company is build a set of assets that could ultimately significantly replace Humira in the marketplace and be superior to Humira.\"</p>\n<p>Even if there's a dip in profitability, AbbVie has plenty of room to support its dividend. And with other pharma stocks like&nbsp;<b>Pfizer</b>,<b>Merck</b>, and&nbsp;<b>Amgen</b>&nbsp;trading at forward&nbsp;price-to-earnings(P/E) multiples of more than 12, AbbVie's multiple of nine makes the stock look like a bargain buy.</p>\n<p>2. ViacomCBS</p>\n<p>Media and entertainment company ViacomCBS pays a dividend that currently yields right around 3% per year. While it's not as high as AbbVie's payout, the stock could more than make up for that with some possibly stronger gains. Viacom currently trades at a forward P/E of less than nine, which is dirt cheap as streaming stocks&nbsp;<b>WaltDisney</b>&nbsp;and&nbsp;<b>Netflix</b>&nbsp;trade at multiples of 35 and 62, respectively.</p>\n<p>One of the reasons investors aren't as bullish on ViacomCBS is that it still isn't a big rival to those streaming giants. At 47 million global streaming subscribers across its services (including Paramount+), ViacomCBS is nowhere near Netflix's tally of 214 million and has a long way to go in catching up to Disney at over 118 million.</p>\n<p>Plus, ViacomCBS's streaming service isn't even the biggest part of its business. In the latest quarter, its advertising, affiliate, and licensing segments together contributed the vast majority of the company's revenue -- about $5.5 billion in all. However, this latest quarter marked the first time that its global streaming revenue surpassed $1 billion. And with revenue growth of 72% over the year-ago period, streaming is by far the company's fastest-growing segment.</p>\n<p>Although it may not be as popular as its bigger-name rivals, ViacomCBS is posting some strong results of late and it could be an&nbsp;attractive contrarian betto take. Plus, its dividend makes it an even better buy.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Ridiculously Cheap Dividend Stocks To Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Ridiculously Cheap Dividend Stocks To Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 11:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/01/2-ridiculously-cheap-dividend-stocks-to-buy-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.\nFor investors ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/01/2-ridiculously-cheap-dividend-stocks-to-buy-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/12/01/2-ridiculously-cheap-dividend-stocks-to-buy-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182613816","content_text":"The S&P 500had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.\nFor investors looking to get away from this volatility and find more safety, holding dividend stocks in your portfolio can be an excellent decision. They can ensure that you're collecting a recurring stream of income you can use to help offset losses in your portfolio. And at best, they can boost your returns. Two dividend stocks that pay an above-average yield and are incredibly cheap right now are AbbVie(NYSE:ABBV)and ViacomCBS(NASDAQ:VIAC).\n1. AbbVie\nAbbVie makes for an ideal buy-and-forget investment. The healthcare stock yields an impressive 4.8% right now -- well above the S&P 500average of just 1.4%. And the dividend is well supported; in the past 12 months, the company has generated free cash flow of $21.7 billion, more than double the $9 billion in dividends it paid out during that time.\nWhen the company released its latest quarterly earnings results on Oct. 29, it reported sales of $14.3 billion, 11% higher than the year-ago period. The company also raised its guidance for a third time in 2021, anticipating that its adjusted diluted earnings per share will come in between $12.63 and $12.67 for the full year. That's well above the $5.64 in dividends that the company is paying out annually per share. TheDividend Aristocratalso raised its dividend by 8.5% in a hike that will come into effect next year.\nWhile investors may be worried about the company's expiring patent on rhe umatoid arthritis drug Humira, AbbVie's management anticipates that newer drugs like Skyrizi and Rinvoq will generate long-term growth and make up for the inevitable decline in Humira's sales. Both drugs still have a long way to go. In just the latest quarter, they achieved combined sales of $1.2 billion in sales while Humira brought in more than $5.4 billion.\nCEO Richard Gonzalez said, \"What we're basically trying to accomplish with the company is build a set of assets that could ultimately significantly replace Humira in the marketplace and be superior to Humira.\"\nEven if there's a dip in profitability, AbbVie has plenty of room to support its dividend. And with other pharma stocks like Pfizer,Merck, and Amgen trading at forward price-to-earnings(P/E) multiples of more than 12, AbbVie's multiple of nine makes the stock look like a bargain buy.\n2. ViacomCBS\nMedia and entertainment company ViacomCBS pays a dividend that currently yields right around 3% per year. While it's not as high as AbbVie's payout, the stock could more than make up for that with some possibly stronger gains. Viacom currently trades at a forward P/E of less than nine, which is dirt cheap as streaming stocks WaltDisney and Netflix trade at multiples of 35 and 62, respectively.\nOne of the reasons investors aren't as bullish on ViacomCBS is that it still isn't a big rival to those streaming giants. At 47 million global streaming subscribers across its services (including Paramount+), ViacomCBS is nowhere near Netflix's tally of 214 million and has a long way to go in catching up to Disney at over 118 million.\nPlus, ViacomCBS's streaming service isn't even the biggest part of its business. In the latest quarter, its advertising, affiliate, and licensing segments together contributed the vast majority of the company's revenue -- about $5.5 billion in all. However, this latest quarter marked the first time that its global streaming revenue surpassed $1 billion. And with revenue growth of 72% over the year-ago period, streaming is by far the company's fastest-growing segment.\nAlthough it may not be as popular as its bigger-name rivals, ViacomCBS is posting some strong results of late and it could be an attractive contrarian betto take. Plus, its dividend makes it an even better buy.","news_type":1,"symbols_score_info":{"ABBV":0.9,"VIAC":0.9}},"isVote":1,"tweetType":1,"viewCount":2212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603094057,"gmtCreate":1638335746598,"gmtModify":1638335760303,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564105303063302","authorIdStr":"3564105303063302"},"themes":[],"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603094057","repostId":"1101502249","repostType":4,"repost":{"id":"1101502249","kind":"news","pubTimestamp":1638330314,"share":"https://ttm.financial/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","MRNA":"Moderna, Inc.","LLY":"礼来","GILD":"吉利德科学"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1,"symbols_score_info":{"GILD":0.9,"LLY":0.9,"MRNA":0.9,"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}